BioCentury | Sep 21, 2009
Finance

Swiss on a roll

The Swiss biotech space hotted up last week as two of its leading funds, run by HBM Partners, picked up more than $200 million in a couple of trade sale exits, while Evolva S.A. announced...
BioCentury | May 3, 2001
Financial News

Gemin X raises $12.6 million

Gemin X raised C$19.1 million (US$12.6 million) in its second round of financing through Sanderling Venture Partners; Canadian Medical Discoveries Fund; Sofinov; BioCapital Investments; MVI Medical Venture Investments; and Business Development Bank of Canada. Gemin...
BioCentury | Jan 9, 2001
Financial News

Qbiogene raises $20 million

Qbiogene (Montreal, Quebec) raised $20 million in a venture financing. Investors included Vertex Technology Fund; Quebec Solidarity Fund; BioCapital Investments; Double Helix ; New Medical Technologies; PolyTechnos Venture-Partners; Schweizerische Gesellschaft fur Aktienhandel & Research; and...
BioCentury | Jan 2, 2001
Company News

Signase board of directors update

...VP for science and technology at A.M. Pappas; Andre Boulet, VP for scientific affairs at BioCapital Investment...
BioCentury | Oct 30, 2000
Finance

Living up to expectations

Toolkit companies that went public this year enjoy a robust premium on their valuations compared to more mature toolkit plays as well as profitable product companies. Indeed, comparing market cap to projected 2001 revenues, a...
BioCentury | Oct 24, 2000
Financial News

Arpida raises $23 million

Arpida (Basel, Switzerland) raised $23 million in a venture financing. Investors included BioCapital Investments; HealthCap; New Medical Technologies; and 3i Group. The company is developing second generation antimicrobial compounds to treat infections caused by drug-resistant...
BioCentury | Sep 11, 2000
Finance

What Europe needs to follow on

In hot equity markets, U.S. companies traditionally have not been bashful about floating an IPO and then returning in short order with a follow-on. But European biotech companies still face the challenge of convincing investors...
BioCentury | Aug 21, 2000
Finance

Toolkit infatuation

The amount of money being thrown at toolkit IPOs in 2000 still reflects the genomics craze that began in the fourth quarter last year. So far this year, toolkit companies are beating up product IPOs...
BioCentury | Jun 19, 2000
Finance

Ebb & Flow

NewcoGen Group and OneLiberty Ventures today were to announce the formation of Applied Genomic Technology Capital, a venture capital vehicle solely focused on genomics companies. The fund - with the genetically appropriate acronym of "AGTC" - has...
BioCentury | Jun 15, 2000
Financial News

BioCapital postpones offering

BioCapital Investments (TSE:BCK.UN), a publicly traded health care limited partnership, postponed its proposed C$46.5 million (US$31.5 million) Canadian offering due to market conditions. BioCapital was to invest the proceeds in both public and private health...
Items per page:
1 - 10 of 13
BioCentury | Sep 21, 2009
Finance

Swiss on a roll

The Swiss biotech space hotted up last week as two of its leading funds, run by HBM Partners, picked up more than $200 million in a couple of trade sale exits, while Evolva S.A. announced...
BioCentury | May 3, 2001
Financial News

Gemin X raises $12.6 million

Gemin X raised C$19.1 million (US$12.6 million) in its second round of financing through Sanderling Venture Partners; Canadian Medical Discoveries Fund; Sofinov; BioCapital Investments; MVI Medical Venture Investments; and Business Development Bank of Canada. Gemin...
BioCentury | Jan 9, 2001
Financial News

Qbiogene raises $20 million

Qbiogene (Montreal, Quebec) raised $20 million in a venture financing. Investors included Vertex Technology Fund; Quebec Solidarity Fund; BioCapital Investments; Double Helix ; New Medical Technologies; PolyTechnos Venture-Partners; Schweizerische Gesellschaft fur Aktienhandel & Research; and...
BioCentury | Jan 2, 2001
Company News

Signase board of directors update

...VP for science and technology at A.M. Pappas; Andre Boulet, VP for scientific affairs at BioCapital Investment...
BioCentury | Oct 30, 2000
Finance

Living up to expectations

Toolkit companies that went public this year enjoy a robust premium on their valuations compared to more mature toolkit plays as well as profitable product companies. Indeed, comparing market cap to projected 2001 revenues, a...
BioCentury | Oct 24, 2000
Financial News

Arpida raises $23 million

Arpida (Basel, Switzerland) raised $23 million in a venture financing. Investors included BioCapital Investments; HealthCap; New Medical Technologies; and 3i Group. The company is developing second generation antimicrobial compounds to treat infections caused by drug-resistant...
BioCentury | Sep 11, 2000
Finance

What Europe needs to follow on

In hot equity markets, U.S. companies traditionally have not been bashful about floating an IPO and then returning in short order with a follow-on. But European biotech companies still face the challenge of convincing investors...
BioCentury | Aug 21, 2000
Finance

Toolkit infatuation

The amount of money being thrown at toolkit IPOs in 2000 still reflects the genomics craze that began in the fourth quarter last year. So far this year, toolkit companies are beating up product IPOs...
BioCentury | Jun 19, 2000
Finance

Ebb & Flow

NewcoGen Group and OneLiberty Ventures today were to announce the formation of Applied Genomic Technology Capital, a venture capital vehicle solely focused on genomics companies. The fund - with the genetically appropriate acronym of "AGTC" - has...
BioCentury | Jun 15, 2000
Financial News

BioCapital postpones offering

BioCapital Investments (TSE:BCK.UN), a publicly traded health care limited partnership, postponed its proposed C$46.5 million (US$31.5 million) Canadian offering due to market conditions. BioCapital was to invest the proceeds in both public and private health...
Items per page:
1 - 10 of 13